109 related articles for article (PubMed ID: 31503486)
1. (-)-Epigallocatechin 3-
Inacio JDF; Fonseca MS; Almeida-Amaral EE
J Nat Prod; 2019 Sep; 82(9):2664-2667. PubMed ID: 31503486
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
4. Apigenin is a promising molecule for treatment of visceral leishmaniasis.
Emiliano YSS; Almeida-Amaral EE
Front Cell Infect Microbiol; 2023; 13():1066407. PubMed ID: 37091674
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine-Lopinavir Combination Therapy Against
Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Pharmacological Studies of 4-Hydroxyphenyl-Derived Phosphonium Salts Active in a Mouse Model of Visceral Leishmaniasis.
Manzano JI; Cueto-Díaz EJ; Olías-Molero AI; Perea A; Herraiz T; Torrado JJ; Alunda JM; Gamarro F; Dardonville C
J Med Chem; 2019 Dec; 62(23):10664-10675. PubMed ID: 31702921
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Topical Treatment with (-)-Epigallocatechin Gallate, A Green Tea Catechin, in Mice with Cutaneous Leishmaniasis.
Sosa AM; Moya Álvarez A; Bracamonte E; Korenaga M; Marco JD; Barroso PA
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290128
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
9. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
10. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
11. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives.
Tavares J; Ouaissi A; Silva AM; Lin PK; Roy N; Cordeiro-da-Silva A
Parasitol Int; 2012 Jun; 61(2):360-3. PubMed ID: 22155672
[TBL] [Abstract][Full Text] [Related]
12. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
[TBL] [Abstract][Full Text] [Related]
13. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
14. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
15. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.
Cunha-Júnior EF; Andrade-Neto VV; Lima ML; da Costa-Silva TA; Galisteo Junior AJ; Abengózar MA; Barbas C; Rivas L; Almeida-Amaral EE; Tempone AG; Torres-Santos EC
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005281. PubMed ID: 28045892
[TBL] [Abstract][Full Text] [Related]
16. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis.
Durand R; Paul M; Pratlong F; Rivollet D; Dubreuil-Lemaire ML; Houin R; Astier A; Deniau M
Antimicrob Agents Chemother; 1998 Aug; 42(8):2141-3. PubMed ID: 9687425
[TBL] [Abstract][Full Text] [Related]
17. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
18. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.
Murray HW; Hariprashad J
Antimicrob Agents Chemother; 1996 Mar; 40(3):586-7. PubMed ID: 8851575
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
[TBL] [Abstract][Full Text] [Related]
20. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Mendonça DVC; Tavares GSV; Pereira IAG; Oliveira-da-Silva JA; Ramos FF; Lage DP; Machado AS; Carvalho LM; Reis TAR; Carvalho AMRS; Ottoni FM; Ludolf F; Freitas CS; Martins VT; Chávez-Fumagalli MA; Duarte MC; Humbert MV; Roatt BM; Menezes-Souza D; Alves RJ; Coelho EAF
Exp Parasitol; 2022 Feb; 233():108205. PubMed ID: 34968460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
